MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciaa1851

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021

Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?

Pettit Natasha N, Pisano Jennifer, Nguyen Cynthia T, Lew Alison K, Hazra Aniruddha, Sherer Renslow, Mullane Kathleen M

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance <30mL/min or requiring renal replacement therapy). Few studies have evaluated RDV in patients with SRI.

METHODS

Hospitalized patients who received RDV between 1 May 2020 and 31 October 2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality, and length of stay.

RESULTS

Of a total of 135 patients, 20 had SRI. Patients with SRI were significantly older (70 vs 54 years, P = .0001). The incidence of possible AEs was 30% among those with SRI vs 11% without (P = .06). Liver function test (LFT) elevations occurred in 10% vs 4% (P = .28), and serum creatinine (SCr) elevations in 27% vs 6% (P = .02) of patients with SRI vs without, respectively. LFT and SCr elevations were not attributed to RDV in either group. Mortality and length of stay were consistent with historical controls.

CONCLUSIONS

RDV AEs occurred infrequently and overall were not significantly different between those with and without SRI. While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury prior to RDV. The use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity. Additional studies are needed to confirm this finding.

Для цитирования: Pettit Natasha N, Pisano Jennifer, Nguyen Cynthia T, Lew Alison K, Hazra Aniruddha, Sherer Renslow, Mullane Kathleen M. Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021. DOI: 10.1093/cid/ciaa1851.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.